leadf
logo-loader

NA Proactive news snapshot: Medexus Pharmaceuticals, Next Green Wave, Humanigen, Canada Silver Cobalt Works, American Resources UPDATE...

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

Newspapers and laptop
Your daily round-up from the world of Proactive

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) revealed that it has struck an agreement with Geneva, Switzerland-based Westmount Capital for it to provide European investor relations services to the Toronto-based specialty pharma company which has a portfolio of therapeutic drugs. Under the terms of the agreement, Westmount will receive C$5,000 per month for an initial trial of three months starting on November 1. After this the company will consider a possible extension. Westmount will introduce Medexus to various institutional investors, fund managers, family offices and other potential investors in Europe. 

Next Green Wave Holdings Inc (CSE:NGW) (OTCQX:NXGWF) announced Friday that its chairman Robert Dzisiak had resigned from his position to explore new business opportunities, according to the Vancouver-based cannabis firm. In a statement, the company said that Dzisiak was “instrumental in helping guide the company through many industry challenges throughout 2020” and wished him all the best in his future endeavors. Next Green Wave did not announce a replacement for the outgoing chairman.

Humanigen Inc (NASDAQ:HGEN), which is focused on preventing and treating the immune hyper-response called ‘cytokine storm’ with lenzilumab, announced Friday that MedStar Washington Hospital Center in Washington, DC treated its first COVID-19 patient with the drug. The Burlingame, California-based company said the primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many as 89% of hospitalized patients with COVID-19 are at risk of a complication called cytokine storm, a harmful inflammation that has been the leading cause of COVID-19 death. Humanigen noted that MedStar Washington Hospital Center is one of 18 sites in the US approved to enroll eligible patients to study lenzilumab, designed specifically to stop this storm. Eligible patients can participate in this trial while also receiving other standard-of-care therapies as recommended by their treating physician.

Canada Silver Cobalt Works (CVE:CCW) (OTCQB:CCWOF) struck a deal with MagNor Resources on Friday to earn 100% interest in the latter’s B2 property in Quebec. B2 consists of 12 claims totaling 670 hectares in the Lac-St-Jean region of Quebec. Mineralization is traceable along strike over one kilometre and open in all directions, according to CCW. Samples taken from the property were assayed and returned results showing massive nickel-copper-cobalt mineralization, with grades of up to 1.1% nickel, 0.6% copper and 0.2% cobalt.

American Resources Corporation (NASDAQ:AREC) reported another profitable quarter that saw the infrastructure company deliver $128,000 in net income, according to third-quarter results released Friday. The results are a sharp contrast to the period a year prior when the Fishers, Indiana-based firm posted a net loss of $7.3 million. CEO Mark Jensen told shareholders that the firm is at the beginning of a “new era” after embarking on a strategic path to transform itself from a pure-play coal miner into an integrated infrastructure company that produces pure metallurgical carbon, rare earth elements and metal aggregation.

MagicMed Industries Inc is teaming up with the University of Calgary to boost the development of the firm’s Psybrary, a molecular derivatives library. The Calgary-based company announced Friday that it entered into a research contract and facilities use agreement with the university, giving it further scientific and laboratory support. In a statement, MagicMed said it will be able to leverage state-of-the-art equipment and laboratory space and draw upon the institution’s “world class” expertise.

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Friday that CEO Thomas Equels has been named the Weaver H Gaines Entrepreneur of the Year by BioFlorida, the voice of the state’s life science industry. The Entrepreneur of the Year Award recognizes an entrepreneur who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. BioFlorida represents 6,700 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT, and bioagriculture sectors. AIM, based in Ocala, Florida, is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Water Tower Research (WTR) announced that it will host Extreme Networks Inc (NASDAQ:EXTR) CEO Ed Meyercord on Friday at its ongoing virtual conference and Fireside Chat series. The event will take place on October 30 at 2pm ET. The live event will also be archived and available for replay. Extreme Networks designs, develops, and manufactures wired and wireless network infrastructure equipment and offers high-density Wi-Fi, centralized management, cloud-based network management, and application analytics capabilities. “The decades ahead should bode well for communications equipment. The positive trends of 5G, remote workers, and cloud should drive carriers, enterprises, governments, education, and industry to upgrade their networks,” said John Roy, who is the managing director of IT Hardware and Communications Equipment Research at Water Tower Research.

Genprex Inc (NASDAQ:GNPX) has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrissoib and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC). These trials will use the brand name, “Acclaim,” which the company believes evokes the enthusiasm and hope these trials represent for NSCLC patients and the oncology community. Acclaim-1 will refer to the Tagrisso combination clinical trial, and Acclaim-2 will refer to the Keytruda combination clinical trial. The idea is to encourage early exposure of Genprex’s clinical programs to patients, healthcare practitioners, clinical investigators, investors, employees and others. The company plans to initiate both Acclaim clinical trials in the first-half of 2021. 

Algernon Pharmaceuticals Inc (CSE:AGN), (OTCQB:AGNPF) (FRA:AGW) announced Friday that the Data and Safety Monitoring Board (DSMB) has once again unanimously approved the continuation of the company’s multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The DSMB is a committee of clinical research experts, including physicians, statisticians, and patient advocates, who are monitoring the progress of the company’s clinical trial, and are reviewing safety and effectiveness data while the trial is ongoing. The board’s decision came after a second meeting and review.

Loop Insights Inc (CVE:MTRX) (OTCMKTS:RACMF), a provider of contact tracing and artificial intelligence to drive automated marketing, said the early response from its webinar with Amazon Web Services (AWS) to showcase Loop’s Venue Tracing Solution smashed expectations with inquiries pouring in from all parts of the globe. Mike Apted, the principal solutions architect at Amazon.com Inc’s (NASDAQ:AMZN) (FRA:AMZ) AWS division, and Loop CEO Rob Anson co-hosted the October 29 event, which provided invitees with a first-hand, interactive taste of Loop's end-to-end Venue Tracing platform.

Esports Entertainment Group Inc (NASDAQ:GMBL) (FRA:40Y1), a licensed online gambling company with a focus on esports wagering and 18+ gaming, has reached a deal to become the official esports tournament provider of the Philadelphia Union Major League Soccer team. The company will host tournaments for the Union on its Esports Gaming League (EGL) platform, giving the team new ways to engage its fans while demonstrating the crossover appeal of esports to traditional sports fans and organizations. Tournament prizes, including merchandise and fan experiences, will be provided by the Union, the company said. 

BioSig Technologies Inc (NASDAQ:BSGM) announced Thursday that it has completed the installation of its PURE EP System at the Deborah Heart and Lung Center in Browns Mills, New Jersey. In a statement, the company said its PURE EP System is also undergoing an evaluation and clinical data collection at the center, under the leadership of Dr Raffaele Corbisiero.

Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF) (FRA:M5BQ) saw its revenue increase by 49% to C$5.6 million in its third-quarter 2020, thanks to blockbuster growth from its online cannabis platform CannMart. Total net revenue for CannMart for the three-month period to end August 31 was C$2.3 million, a 1,586% increase compared to the year-ago period, according to results released Friday. Cannabis revenue represented nearly 41% of net consolidated revenue for the quarter versus 3.6% in the same period a year prior.

Vuzix Corporation (NASDAQ:VUZI) revealed on Thursday that Valmet, a top global technology and services provider to the pulp, paper and energy industries, is utilizing its Vuzix M400 Smart Glasses at an industrial plant belonging to South American paper company CMPC. The Rochester, New York-based company said the Vuzix M400 Smart Glasses were being used to provide remote support between specialists and employees. TotalPower Brazil, the company's main distributor in the region, won the Valmet account. Amid the coronavirus (COVID-19) pandemic, CMPC scheduled a 10-day maintenance shutdown at its Guaíbal plant in Brazil, implementing a strict prevention protocol for COVID-19, while employing solutions that could remotely address some of the plant's operational demands. The company said Vuzix’s augmented reality smart glasses were used during the shutdown, enabling “detailed analysis by Valmet specialists without their physical presence on premises being necessary.”

NetCents Technology Inc (CSE:NC) (OTCQB:NTTCF) (FRA:26N), a cryptocurrency payments company, announced Friday that it has increased its credit facility from US$1.4 billion to US$2 billion. The company said it has made the move to facilitate continued merchant growth, a credit card launch, and white label projects. NetCents said it is preparing for rapid growth in the cryptocurrency space specifically B2B payments as its transaction volume is rising and user adoption is growing rapidly.

Antibe Therapeutics Inc. (CVE:ATE) (OTCQB:ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, announced that it has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its common shares on the TSX. “Graduating to the TSX is an important milestone for Antibe, reflecting both our progress and potential,” said Dan Legault, Antibe’s CEO in a statement. “With partnering activities expanding and preparations for our first Phase III study fully underway, this is the right time to broaden our investor base and raise the Company’s profile in the investment community. We appreciate the support of our shareholders and the efforts of the TSXV and TSX as we implement the next phase of our corporate strategy."

NexTech AR Solutions Corp (OTCQB:NEXCF) (CSE:NTAR) (FRA:N29), an emerging leader in augmented reality for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events has announced that its CEO Evan Gappelberg will present live at VirtualInvestorConferences.com on November 5, 2020, at 12.30pm ET. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. The presentation can viewed on the day via this link: https://bit.ly/2HDdBgd. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Bioasis Technologies Inc. (CVE:BTI.V) (OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of central nervous system disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, said it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended August 31, 2020. All are available under the company’s profile on SEDAR at www.sedar.com and on the company’s website at www.bioasis.us

Media Central Corporation Inc. (CSE:FLYY) (FRA:3AT) has announced the date for a Special Meeting of Shareholders as December 30, 2020, following receipt of a shareholder requisition. The company said it worked in the most expeditious manner possible to schedule this meeting, after its board of directors took the necessary time to review the requisition materials and to consult with a variety of stakeholders including shareholders who reached out to the company to express their concerns with the actions of the dissident shareholders. The company said it is grateful for the support expressed for the current leadership. "During our 2020 AGM, we saw over 57% of the issued and outstanding shares of Media Central vote their shares and the majority expressed their confidence in the Company by duly re-electing the Board of Directors," stated Brian Kalish, president and CEO. "While this is an unfortunate disruption especially in these times, we remain committed to ensuring that every shareholder of Media Central has the ability to have their voice heard."

Aurania Resources Ltd (CVE:ARU) said the company's short-form offering prospectus dated October 22, 2020, was filed with and accepted by the TSX Venture Exchange and filed with and receipted by the securities regulatory authorities of British Columbia and Ontario pursuant to the provisions of the respective securities act. The offering consisted of 2.33 million units at a price of $4.30 per unit. Each unit comprises one common share and one-half common share purchase warrant. Each whole warrant entitles its holder to purchase one additional common share at the exercise price of $5.50 per share during a period of 24 months following the closing of the offering.

Klondike Gold Corp. (CVE:KG)(FRA:LBDP) has said that under the company's stock option plan, a total of 2,450,000 incentive stock options have been granted to directors, officers, employees, and consultants of the company. The options are exercisable at a price of $0.25 per share for a period of 10 years, subject to regulatory approval.

Dyadic International, Inc. (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, thas said it will report its financial results for the quarter ended September 30, 2020, after the market close on Thursday, November 12, 2020 and it will host a conference call that day at 5.00pm Eastern Time to discuss those results. Conference Call Dial-in numbers: (877) 407-8033 (U.S. or Canada) or +(201) 689-8033 (International); No passcode is needed; Webcast Link: https://www.webcaster4.com/Webcast/Page/2031/38362. An archive of the webcast will be available approximately three hours after completion of the live event and will be accessible on the "Investors" section of the company's website at www.dyadic.com. To access the replay of the webcast, please follow the Webcast link above. A dial-in replay of the call will also be available to those interested. To access the replay, please dial 1 (877) 481-4010 (U.S. or Canada) or 1 (919) 882-2331 (International) and enter replay pass code: 38362.

Phunware, Inc. (NASDAQ:PHUN), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, said it will hold a conference call on Monday, November 9, 2020, at 5.00pm Eastern time to discuss its financial results for the third quarter ended September 30, 2020, which will be issued in a press release prior to the call. Phunware management will host the conference call, followed by a question and answer period. Conference call access details: US dial-in number: (844) 369-8770; International number: (862) 298-0840. The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website at investors.phunware.com.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Sativa Wellness Group salute EU court ruling that CBD is not classified as...

Sativa Wellness Group Inc's (LON:SWEL) Henry Lees-Buckley talks to Proactive London about the latest ruling from the European Court of Justice (ECJ) that CBD is not classified as a narcotic drug and that a French ban on hemp derived CBD contradicts EU law. Lees-Buckley says because they...

29 minutes ago

13 min read